INNOVENT BIO (01801): The stock price has seen some volatility, but the company's business operations are running smoothly and there have been no changes.

INNOVENT BIO (01801) announces that the company has noticed abnormal fluctuations in its stock price and trading volume recently. The company clarifies that its business operations are normal and there have been no changes. After reasonable investigation, the board confirms that as of the date of this announcement, they are not aware of any information that needs to be disclosed to prevent false market or any insider information under the Hong Kong Securities and Futures Ordinance Chapter 571. Under the strategic goal of "sustainable development and global innovation" in the second decade, the company has achieved excellent results in the past and reached significant milestones. Looking ahead, the company believes that 2025 will be a year for rapid business growth and further strengthening of global innovation capabilities. INNOVENT BIO has become a leading brand in the field of oncology treatment and is gaining momentum with an expanding synergistic product portfolio. In addition, the comprehensive product line, as the second growth pillar of the company, with its competitive product portfolio (including MASDOGLUPEptide (GCG/GLP-1), TORAYMONOAB (IGF-1R), and PICONGQIBAI MONOAB (IL-23p19)) will unlock high potential markets for chronic diseases, with these products currently under review by the China National Medical Products Administration. The company is confident in achieving a target of RMB 20 billion in domestic product revenue by 2027. While maintaining high-speed business growth, the company focuses on lean operations and continuous improvement towards sustainable and healthy operations. Meanwhile, the company's new generation pipeline is opening up new opportunities for global development. The new generation innovative pipeline, represented by IO and ADC, is gradually welcoming new global development opportunities. In the future, the company will have more innovative ADCs, bispecific (multi-specific) antibodies, next-generation immune-oncology and cardiovascular and metabolic (CVM) therapies entering global development. The company remains committed to its short-term and long-term growth and is confident in this approach. The company will continue to steadfastly move towards its vision of becoming a world-class international biopharmaceutical company.